In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 34127-22-5, name is Ethyl 3,6-dichloropyridazine-4-carboxylate, introducing its new discovery. SDS of cas: 34127-22-5
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson’s disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed.
I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 34127-22-5, help many people in the next few years.SDS of cas: 34127-22-5
Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N2958 – PubChem